OCUGEN, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
OCUGEN, INC. (OCGN) had Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $900.00 thousand as of 2019-05-16, per its 10-K filed 2021-03-19.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2021-03-19
- 2019-05-16: Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature $900.00K.
- 2019-04-05: Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature $13.00M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature |
|---|---|
| 2019-05-16 | $900.00K 10-K · filed 2021-03-19 |
| 2019-04-05 | $13.00M 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |